| abstract |
The invention concerns derivatives of formula (I), wherein R1 represents -OH, (C1-C5) alkoxy, carboxyl, (C2-C6) alkoxycarbonyl, -NR5R6, -NH-SO2-Alk, -NH-SO2-Ph, -NH-CO-Ph, -N(Alk)-CO-Ph, -NH-CO-NH-Ph, -NH-CO-Alk, -NH-CO2-alk,-O-(CH2)n-cAlk, -O-Alk-COOR7,-O-Alk-O-R8,-O-Alk-OH, -O-Alk-C(NH2):NOH, -O-Alk-NR5R6, -O-Alk-CN, -O-(CH2)n-Ph, -O-Alk-CO-NR5R6, -CO-NH-(CH2)m-COOR7, -CO-NH-Alk; R2 represents H, (C1-C5) alkyl, (C1-C5) alkyl halide, (C3-C6) cycloalkyl or phenyl optionally substituted; A represents -CO-, -SO- or -SO2-; R3 and R4 identical or different represent each H, (C1-C5) alcoxyl, amino, carboxy, (C2-C6) alkoxycarbonyl, -OH, nitro, hydroxyamino, -Alk-COOR7, -NR5R6, -NH-Alk-COOR7, -NH-COO-Alk, -N(R11)-SO2-Alk-NR9R10, -N(R11)-SO2-Alk,-N(R11)-Alk-NR5R6, -N(R11)-CO-Alk-NR9R10, -N(R11)-CO-Alk, -N(R11)-CO-CF3, -NH-Alk-HetN, -O-Alk-NR9R10, -O-Alk-CO-NR5R6, -O-Alk-HetN, or R3 and R4 form together an unsaturated heterocycle of 5 to 6 members, optionally in the form of one of their pharmaceutically acceptable salts. |